Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
REGN 
Regeneron Pharmaceuticals Inc (REGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: REGN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
25 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $737.92
Year Target Price $737.92
| 14 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.59% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 56.25B USD | Price to earnings Ratio 13.24 | 1Y Target Price 727.21 |
Price to earnings Ratio 13.24 | 1Y Target Price 727.21 | ||
Volume (30-day avg) - | Beta 0.31 | 52 Weeks Range 476.49 - 1207.86 | Updated Date 06/29/2025 |
52 Weeks Range 476.49 - 1207.86 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.68% | Basic EPS (TTM) 39.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 31.94% | Operating Margin (TTM) 19.94% |
Management Effectiveness
Return on Assets (TTM) 6.91% | Return on Equity (TTM) 15.96% |
Valuation
Trailing PE 13.24 | Forward PE 14.24 | Enterprise Value 50605423937 | Price to Sales(TTM) 3.99 |
Enterprise Value 50605423937 | Price to Sales(TTM) 3.99 | ||
Enterprise Value to Revenue 3.59 | Enterprise Value to EBITDA 9.15 | Shares Outstanding 106148000 | Shares Floating 99889821 |
Shares Outstanding 106148000 | Shares Floating 99889821 | ||
Percent Insiders 1.9 | Percent Institutions 92.12 |
Analyst Ratings
Rating 4.28 | Target Price 737.92 | Buy 5 | Strong Buy 14 |
Buy 5 | Strong Buy 14 | ||
Hold 5 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Regeneron Pharmaceuticals Inc
Company Overview
History and Background
Regeneron Pharmaceuticals Inc. was founded in 1988 by Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D. Initially focused on neurotrophic factors, it evolved into a fully integrated biopharmaceutical company discovering, developing, and commercializing medicines for serious diseases.
Core Business Areas
- Eye Disease: Develops and commercializes therapies for eye diseases, including macular degeneration and diabetic eye disease.
- Allergic and Inflammatory Diseases: Develops and commercializes therapies for allergic conditions like asthma and atopic dermatitis.
- Cancer: Develops therapies to treat different types of cancers.
- Cardiovascular Disease: Develops therapies to treat cardiovascular diseases.
- Infectious Diseases: Develops therapies to treat infectious diseases, including COVID-19.
Leadership and Structure
Leonard S. Schleifer is the Founder, President, and CEO. George D. Yancopoulos is the Founder, President, and Chief Scientific Officer. The company has a typical corporate structure with various departments including R&D, Commercial, and Operations.
Top Products and Market Share
Key Offerings
- Eylea (aflibercept): A VEGF inhibitor used to treat wet age-related macular degeneration, diabetic retinopathy, and other eye conditions. Competitors: Lucentis (Roche/Novartis), Beovu (Novartis). Eylea sales for Regeneron were $5.9 billion in 2023 (global excluding Bayer's share).
- Dupixent (dupilumab): An antibody targeting IL-4 and IL-13 used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, developed and commercialized with Sanofi. Competitors: Adbry (LEO Pharma), Rinvoq (AbbVie), Cibinqo (Pfizer). Global Dupixent sales were $9.3 billion in 2023 (Regeneron recognizes their share of US profits).
- Libtayo (cemiplimab): A PD-1 inhibitor used to treat certain types of skin cancer and lung cancer. Competitors: Keytruda (Merck), Opdivo (Bristol Myers Squibb). Libtayo global sales were $794 million in 2023.
- Praluent (alirocumab): A PCSK9 inhibitor used to lower cholesterol, developed and commercialized with Sanofi. Competitors: Repatha (Amgen). Praluent Net Product Sales in US $212 million for 2023.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Key trends include personalized medicine, gene therapy, and increasing focus on chronic diseases.
Positioning
Regeneron is a leader in antibody-based therapies and has a strong R&D pipeline. Its competitive advantage lies in its proprietary VelociSuite technologies, which enable rapid discovery and development of new drugs.
Total Addressable Market (TAM)
The global pharmaceutical market is expected to reach over $1.7 trillion by 2027. Regeneron is positioned to capture a significant share of this TAM through its innovative products and strong R&D pipeline.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Proprietary VelociSuite technologies
- Successful commercialization of key products (Eylea, Dupixent)
- Experienced management team
- Strategic collaborations (e.g., Sanofi)
Weaknesses
- Reliance on key products
- Patent expiration risks
- Competition from other pharmaceutical companies
- Dependence on collaborations
Opportunities
- Expansion into new therapeutic areas
- Development of novel drug modalities
- Acquisitions and partnerships
- Growing global demand for pharmaceuticals
Threats
- Regulatory hurdles
- Pricing pressures
- Generic competition
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- MRK
- ABBV
- AMGN
- BMY
- SNY
Competitive Landscape
Regeneron faces intense competition from other large pharmaceutical companies. Its competitive advantage lies in its innovative technology and strong R&D pipeline. However, it is also vulnerable to patent expirations and generic competition.
Major Acquisitions
Decibel Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 109
- Strategic Rationale: Expand capabilities in hearing loss therapies.
Growth Trajectory and Initiatives
Historical Growth: Regeneron experienced rapid growth in the past decade, driven by the success of Eylea and Dupixent.
Future Projections: Analysts project continued growth for Regeneron, driven by new product launches and expansion of existing products into new indications. However, growth is expected to be slower than in the past.
Recent Initiatives: Regeneron is investing in new technologies and therapeutic areas, including gene therapy and oncology. The company is also expanding its global presence.
Summary
Regeneron is a strong biopharmaceutical company with a history of innovation and successful product launches. Its proprietary VelociSuite technologies provide a competitive advantage. However, the company faces challenges related to competition, patent expirations, and regulatory hurdles. It needs to continue investing in R&D and diversifying its product portfolio to sustain long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Regeneron Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- Third Party Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regeneron Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Tarrytown, NY, United States | ||
IPO Launch date 1991-04-02 | Co-Founder, President, CEO & Co-Chairman Dr. Leonard S. Schleifer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15158 | Website https://www.regeneron.com |
Full time employees 15158 | Website https://www.regeneron.com | ||
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.